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Abstract
Oxidative stress and oxidative DNA damage are early features of mild cognitive impairment and
Alzheimer's disease (AD), occurring before the formation of classical AD neuropathology, and
resulting from an imbalance between pro- and anti-oxidants. Astrocytes play a major neuropro-
tective role, producing high levels of anti-oxidants including metallothionein-I and -II (MT-I/II).
In the present study we characterized the immunoreactive profile of MT-I/II in the temporal cor-
tex of the Cognitive Function and Ageing Study (CFAS) aging population-representative neuro-
pathology cohort, and examined H2O2-modulation of MT transcription by human astrocytes.
MT-I/II is primarily expressed by astrocytes in the aging brain, but is also associated with pyra-
midal neurons in a small proportion of cases. Astrocyte expression of MT-I/II does not correlate
with Alzheimer-type pathology (Aβ plaques and neurofibrillary tangles) but does relate to astro-
cyte oxidative DNA damage (rs = .312, p = .006) and the astrocyte response to oxidative DNA
damage in vivo (rs = .238, p = .04), and MT gene expression is significantly induced in human
astrocytes response to oxidative stress in vitro (p = .01). In contrast, neuronal MT-I/II does not
relate to oxidative DNA damage or the neuronal DNA damage response, but is significantly
higher in cases with high levels of local tangle pathology (p = .007). As MT-I/II is neuroprotec-
tive against oxidative stress, modulation of MT-I/II expression is a potential therapeutic target
to treat the onset and progression of cognitive impairment.
1. MT-I/II is expressed by astrocytes in the aging brain.
2. MT-I/II expression does not correlate with Alzheimer pathology but to astrocyte oxidative
DNA damage in vivo.
3. In response to oxidative stressMT genes are induced in human astrocytes in vitro.
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1 | INTRODUCTION
Oxidative stress is a feature of brain aging which gives rise to the oxi-
dative modification of proteins, lipids, DNA and RNA and plays a key
role in several neurodegenerative pathologies, including Alzheimer's
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disease (AD). Both oxidative stress and oxidative DNA damage are
early features of mild cognitive impairment (MCI) and AD, occurring
before the formation of classical AD neuropathology, including extra-
cellular deposits of β-amyloid peptides (Aβ plaques) and intracellular
deposits of hyperphosphorylated tau (neurofibrillary tangles, NFT;
Keller et al., 2005; Nunomura et al., 2006; Nunomura et al., 2001).
Oxidative DNA damage, in particular DNA double-strand breaks,
is a potent inducer of a DNA damage response (DDR), which is char-
acterized by the activation of sensor kinases, including DNA-protein
kinase catalytic subunit (DNA-PKcs), and regions of DNA damage
incorporating phosphorylated histone γH2AX. We have previously
shown an association between the neuronal DDR and cognitive
impairment, independent of AD pathology in the ageing brain
(Simpson et al., 2015), and demonstrated that increased levels of oxi-
dative stress and the astrocyte DDR are an early event and not simply
a secondary response to established AD pathology (Simpson, Ince,
Haynes, et al., 2010).
Astrocytes play a major neuroprotective role, producing high
levels of anti-oxidants (Ben Haim, Carrillo-de Sauvage, Ceyzeriat, &
Escartin, 2015; Liddell, Robinson, Dringen, & Bishop, 2010). Metal-
lothioneins (MT) are low molecular weight cysteine-rich proteins with
a high metal content that can protect against reactive oxygen species
(ROS; Vasak & Meloni, 2011). They comprise four subfamilies: MT-I
and MT-II are present in most tissues, with MT-III and MT-IV expres-
sion confined to the central nervous system (CNS) and stratified squa-
mous epithelium, respectively. While MT-I and -II have a similar
structure, differing only by one amino acid and their ability to bind dif-
ferent metal ions, they are generally expressed in response to the
same stimuli and perform the same function, so they are commonly
grouped together and referred to as MT-I/II (Artells, Palacios, Capde-
vila, & Atrian, 2013). Within the CNS, MT-I/II is predominantly
expressed by astrocytes, but has also been detected in neurons,
microglia and endothelial cells (Pedersen et al., 2009; West, Hidalgo,
Eddins, Levin, & Aschner, 2008), and is highly inducible in response to
a variety of stimuli, including oxidative stress, neuroinflammation and
toxic levels of metal ions (Andrews, 2000; Hidalgo et al., 2006; Manso,
Adlard, Carrasco, Vasak, & Hidalgo, 2011). MT-I/II gene expression is
regulated by antioxidant response elements, and reduced expression
of MT-I/II in cell models or knock out animals results in heightened
sensitivity to oxidative stress (Pitt et al., 1997; Qu, Pi, & Waalkes,
2013). MT-I/II is upregulated in AD (Adlard, West, & Vickers, 1998;
Zambenedetti, Giordano, & Zatta, 1998) and is primarily associated
with Aβ plaques in the hippocampus of several AD animal models
(Carrasco et al., 2006; Hidalgo et al., 2006).
Given the major role oxidative stress plays in the pathogenesis of
neurodegenerative pathologies the present study evaluated MT-I/II
expression in the temporal cortex of the Cognitive Function and Age-
ing Study (CFAS) neuropathology cohort, a well characterized large,
ageing population-representative cohort which facilitates unbiased
assessment of relationships between pathology and dementia, with
the aim of assessing the relationship between MT-I/II and Alzheimer-
type pathology and the association with the astrocyte DDR in the
aging human brain. In addition, the direct effect of oxidative stress on
MT-I/II expression by human astrocytes was also assessed.
2 | MATERIALS AND METHODS
2.1 | Human CNS cases
Human autopsy brain tissue was obtained from one center of the
Cognitive Function and Ageing Study (CFAS), following multi-center
research ethics committee (REC) approval (REC Reference number
15/SW/0246; Wharton et al., 2011). Neuropathological lesions were
assessed as part of the core CFAS neuropathology study using a modi-
fied protocol from the Consortium to Establish a Registry of Alzhei-
mer's Disease (CERAD; wwws.cfas.ac.uk; Mirra, 1997) and Braak
neurofibrillary tangle staging (Braak & Braak, 1991). The cases were
categorized into three groups representing entorhinal stages (Group
1; Braak Stages 0–II; 21 cases), limbic stages (Group 2; Braak Stages
III–IV; 14 cases) and isocortical stages of tangle pathology (Group 3;
Braak Stages V–VI; 43 cases). The mean age of death was 86.8 stan-
dard error of the mean (SEM 6.98) years. The median post-mortem
delay was 16 hr, interquartile range (IQR 9–35.5 hr) and brain pH6.49
(IQR 6.2–6.7). Formalin-fixed lateral temporal cortex samples (supe-
rior/middle temporal gyrus, Brodmann areas 22/21) were available for
all cases. The astrocyte DDR (γH2AX nuclear immunoreactivity), oxi-
dative DNA damage (8-hydroxydeoxyguanosine, 8-OHdG), astroglio-
sis (GFAP), and local measures of AD-type pathology (Aβ and AT8)
were previously assessed in these cases (Simpson, Ince, Haynes, et al.,
2010; Simpson, Ince, Lace, et al., 2010; Wharton et al., 2009). A total
of 78 participants were included in these analyses, where 48 were
female.
2.2 | Immunohistochemistry
Immunohistochemistry was performed using a standard avidin-biotin
complex (ABC) method. Sections were deparaffinized, rehydrated to
water and endogenous peroxidase activity quenched by placing the
sections in 0.3% H2O2/methanol for 20 min at room temperature
(RT). Sections were subjected to antigen retrieval (Access Super
pH9.5, pressure cooker [Menarini Diagnostics, UK]). Following incuba-
tion with 1.5% normal serum for 30 min at RT, the sections were incu-
bated for 60 min at RT with the well characterized, commercially
available mouse monoclonal antibody against MT-I/II (1:100; DakoCy-
tomation, UK). To visualize antibody binding, the horse-radish peroxi-
dase avidin biotin complex (ABC-HRP) was used (Vectastain Elite kit,
Vector Laboratories, UK) with 3,30-diaminobenzidine (DAB) as the
chromogen (Vector Laboratories, UK; brown). Negative controls,
either omission of the primary antibody or a mouse isotype control,
were included in every run.
To determine if MT-I/II+ astrocytes colocalized with Aβ plaques,
NFT or the astrocyte DDR, sequential dual labeling was performed
with MT-I/II and either Aβ, AT8 or γH2AX. Briefly, amyloid plaques
(mouse monoclonal Aβ 1:100; DakoCytomation, UK), tau tangles
(mouse monoclonal AT8 1:400; Endogen, UK) or the astrocyte DNA
damage response (rabbit polyclonal γH2AX 1: 1,000, R&D Systems,
UK) were first visualized using the standard ABC-HRP protocol with
DAB as substrate described above. For Aβ immunohistochemistry,
antigen retrieval was carried out following pre-treatment with
formic acid for 40 min at RT. Sections were then incubated with the
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avidin-biotin blocking kit (Vector Laboratories, UK), according to the
manufacturer's instructions. The tissue was incubated overnight at
4 C with anti-MT-I/II (1:100), followed by biotinylated secondary
antibody, and visualized with the alkaline-phosphatase-conjugated
avidin-biotin complex and alkaline phosphatase substrate 1 (Vector
Laboratories, UK, red). Every immuno-run included a single-labeled
section, which showed the same pattern and intensity of immunoreac-
tivity as seen in the dual-labeling experiments.
2.3 | Quantitative analysis of MT-I/II
Assessment of MT-I/II-specific immunoreactivity was performed by
capturing bright-field microscopic images in three adjacent 350 μm-
wide cortical ribbons, consisting of contiguous fields to cover the total
cortical thickness through the apex of the gyrus, using a 20 × objec-
tive (Nikon Eclipse Ni-U microscope, Nikon, UK) and analyzed using
the Analysis D^ software (Olympus Biosystems, Watford, UK). The
image was thresholded and the immunoreactive area of the field
determined per total area examined.
2.4 | Primary human astrocytes
Previously characterized (Garwood et al., 2015), human primary astro-
cytes were obtained from ScienCell Research Laboratories (Carlsbad,
CA). Astrocytes were cultured in Human Astrocyte media (ScienCell
Research Laboratories) supplemented with 2% fetal bovine serum
(FBS), 1% penicillin streptomycin and 1% Astrocyte Growth Supple-
ment (ScienCell Research Laboratories). To characterize the effect of
oxidative stress in MT-I/II expression, astrocytes were cultured in the
presence and absence of 50 μM hydrogen peroxide (H2O2) for 1 or
24 hr at passage 7. Cell viability tests were not performed, however
previous studies have shown that this concentration of H2O2 is suble-
thal to astrocytes (Crowe et al., 2016).
2.5 | Immunocytochemistry
Cells were fixed in 4% paraformaldehyde in PBS for 5 min at 37 C,
then permeabilized (0.3% Triton X-100 in PBS) and blocked with 3%
bovine serum albumin for 20 min at RT. Cells were incubated with
MT-I/II (1:100) for 60 min at RT, followed by biotinylated secondary
antibody, and visualized with streptavidin alexa fluor 488 (1:500).
Nuclei were counterstained with Hoechst 33342, and the staining
visualized using a Nikon Eclipse Ni-U microscope (Nikon, Kingston
upon Thames, UK).
2.6 | Quantitative real-time polymerase chain
reaction (qPCR)
Cultured astrocytes were washed with PBS and lysed in 110 μl
(1 ml/10 cm2) Trizol (Thermoscientific, UK). RNA was isolated using
the Direct-Zol RNA Miniprep Kit with Zymo-Spin IIC Columns (Zymo,
Irvine, CA) and total RNA (500 ng) was incubated at 25 C for 5 min
and reverse transcribed at 42 C for 30 min followed by incubation at
85 C for 5 min in a reaction mix containing qScript (Quanta Biosci-
ences, Gaithersburg, MD). qPCR was performed using IDT PrimeTime
qPCR assays (Integrated DNA Technologies, UK) containing 50 ng
cDNA, 500 nM primers, 250 nM probe, and Brilliant qPCR mix (Agilent,
UK). Primers for MT2A and β-actin were designed to span between
adjacent exons (MT2A Primer 1: 50- AGCTTTTCTTGCAGGAGGTG-30,
Primer 2: 50-GCAACCTGTCCCGACTCTA-30 , probe: 50-FAM-AGCTCGC-
CATGGATCCCAACT-30; β-actin Primer 1: 50-GTCCCCCAACTTGA-
GATGTATG-30, Primer 2: 50-AAGTCAGTGTACAGGTAAGCC-30 , probe:
50-FAM-CCATGTACGTTGCTATCCAGGCTGT-30). Following denatur-
ation at 95 C for 3 min the products were amplified (40 cycles at 95 C
for 10 s and 60 C for 30 s) using a CFX384 Touch RT PCR detection
system (Bio-Rad, UK). β-actin was amplified on each plate to normalize
expression levels of target genes between different samples using the
ΔΔCt calculation (ABI) and to assess assay reproducibility.
2.6.1 | Statistical analysis
As the immunohistochemistry data was skewed, median and inter-
quartile range (IQR) was used for descriptive analyses. Spearman's
correlation coefficient (rs) was calculated to verify the strength of cor-
relations between continuous variables, and Kruskal-Wallis (KW) to
test the correlation with parametric data. All tests were two-tailed.
Student's paired t test was used to analyze the qPCR data. Statistical
analyses were performed using statistical package IBM SPSS Statistics
version 23 and GraphPad Prism version 7.
3 | RESULTS
3.1 | MT-I/II predominantly immunolabels
astrocytes in the aging human temporal cortex
MT-I/II was associated with astrocytes, predominantly staining the
astrocyte cell body and their primary radiating processes throughout
layers II–VI of the temporal cortex (Figure 1a). A punctate pattern of
staining was observed throughout the parenchyma, likely reflecting
immunolabeling of cross-sections of the astrocyte processes. The pat-
tern and intensity of immunoreactivity varied greatly across the
cohort (median 7.31%, IQR 5.77), with some cases showing reduced
staining, particularly surrounding blood vessels (Figure 1b).
While MT-I/II predominantly labeled astrocytes, weak immunore-
activity was also associated with a subpopulation of neurons in 16.6%
of cases (13 out of 78 cases, Figure 1c), but no microglial, oligoden-
drocyte, or endothelial staining was detected. The immunoreactivity
associated with capillaries and blood vessels likely represents MT-I/II+
astrocytes, whose foot processes line the blood brain barrier
(Figure 1d). No specific immunoreactivity was observed in the nega-
tive controls.
3.2 | Astrocyte expression of MT-I/II does not relate
to global or local Alzheimer-type pathology
To analyze the relationship of MT-I/II+ astrocytes with measures of
global Alzheimer-type pathology the variation of expression was
determined between Braak and Braak neurofibrillary tangle groups
(entorhinal, Stages I–II; limbic, Stages III–IV; isocortical, Stages V–VI).
There were no differences in MT-I/II expression between Braak and
Braak groups (Kruskal-Wallis p = .314) (Figure 2a). We also compared
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MT-I/II to measures of local AD neuropathology in temporal cortex.
For comparisons with CERAD scores of diffuse and neuritic plaques
and neurofibrillary tangles, the moderate-severe score groups were
combined. MT-I/II expression was not associated with neuritic pla-
ques (Kruskal-Wallis p = .697), diffuse plaques (p = .871) or neurofi-
brillary tangles (p = .891) and there were no correlations with area
immunoreactivity for phospho-tau (AT8; Spearman's rank, rs = .081,
p = .498) or Aβ (rs = .001, p = .99). MT-I/II expression did not corre-
late with post-mortem delay (rs = .113, p = .37) or brain pH (rs = .038,
p = .771). Furthermore, dual labeling demonstrated that while MT-I/
II+ astrocytes were a prominent feature of the aging brain, they did
not intimately associate with the majority of Aβ plaques (Figure 1e).
3.3 | Cases with MT-I/II + neurons have higher
levels of local tau pathology
MT-I/II+ neurons were present in a small number of the cases
assessed in this study (13 out of 78 cases). To determine if MT-I/II+
FIGURE 1 MT-I/II expression in the aging brain. (a) MT-I/II predominantly immunolabeled astrocyte cell bodies and primary radiating processes.
(b) A reduced pattern of staining was observed in some cases, particularly surrounding blood vessels (v). (c) MT-I/II+ neurons were present in some
cases (indicated by the arrows). (d) The staining associated with blood vessels likely represents MT-I/II+ astrocyte foot processes (indicated by the
arrows). (e) MT-I/II+ astrocytes (red) were not associated with Aβ plaques (brown). (f ) In contrast, nuclear immunoreactivity for γH2AX (brown)
was detected in a proportion of MT-I/II+ astrocytes (red). Scale bar represents 50 μm [Color figure can be viewed at wieyonlinelibrary.com]
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neurons related to AD pathology, the cases were dichotomized into
low (Braak and Braak Stages I–III) and high Braak stages (Braak and
Braak stages IV-VI). The proportion of cases with MT-I/II+ neurons
was significantly higher in the high Braak stage group (28%) com-
pared with the low Braak stage group (7%; Chi Square 1df,
χ2 = 5.94, p = .015). We further tested whether cases with MT-I/II+
neurons had higher levels of local AD-type pathology. AT8 immuno-
reactivity (% area) was higher in cases with MT-I/II+ neurons com-
pared with cases without (median 2.2% vs. 0.35%, p = .007;
Figure 2b), whereas there was no difference in Aβ immunoreactivity
(% area). Additionally, there was no difference in the proportion of
γH2AX+ neurons in cases with MT-I/II+ neurons compared with
cases without, demonstrating that MT-I/II+ neurons are not associ-
ated with the neuronal DNA damage response.
3.4 | Astrocyte expression of MT-I/II correlates with
the astrocytic DNA damage response
As MT-I/II plays an anti-oxidant role, we investigated the relationship
between MT-I/II expression, oxidative DNA damage and the astrocyte
DNA damage response in the ageing brain. MT-I/II expression
significantly correlates with the number of 8OHdG+ glia (rs = 0.312,
p = .006; Figure 2c) and γH2AX+ astrocytes in the ageing temporal
cortex (rs = .238, p = .04; Figure 2d). Dual labeling confirmed nuclear
immunoreactivity for γH2AX in a proportion of MT-I/II+ astrocytes
(Figure 1f ).
3.5 | Oxidative stress induces MT-I/II expression in
human astrocytes in vitro
Human astrocytes were cultured with a sublethal dose of H2O2 to fur-
ther investigate the effect of oxidative stress on MT expression.
Treatment with 50 μM H2O2 for 1 hr did not significantly impact
MT2A mRNA levels, but after 24 hr significantly upregulated MT2A
expression was observed (n = 3, p = .01; Figure 3a). To determine if
changes in mRNA impacted translation we evaluated MT-I/II expres-
sion by immunocytochemistry. Similar to the qPCR results, low levels
of MT-I/II were detected in untreated human astrocytes (Figure 3b).
Treatment with 50 μM H2O2 for 24 hr increased the expression of
MT-I/II, both in the cytoplasmic and nuclear compartments in vitro
(Figure 3c).
FIGURE 2 MT-I/II expression is associated with the astrocyte response to DNA damage. (a) MT-I/II expression did not associate with global
Alzheimer-type pathology (Braak stage). (b) In contrast, cases with MT-I/II + neurons had significantly higher levels of tau pathology (AT8% area
immunoreactivity, p = .007). (c) MT-I/II expression significantly correlates with the number of 8OHdG + glia (rs = .312, p = .006) and
(d) γH2AX + astrocytes in the aging temporal cortex (rs = .238, p = .04)
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4 | DISCUSSION
Oxidative stress and the associated oxidative-induced damage plays a
key role in the initiation and progression of AD (Keller et al., 2005;
Nunomura et al., 2006; Nunomura et al., 2001). In the current study
we demonstrate that MT-I/II expression is predominantly associated
with astrocytes in the ageing brain. Expression of this anti-oxidant
does not correlate with Alzheimer-type pathology but does relate to
the astrocyte response to oxidative DNA damage in vivo, and is
induced in human astrocytes in response to oxidative stress in vitro.
Within the aging temporal cortex MT-I/II is predominantly associ-
ated with astrocytes, supporting previous studies in AD (Adlard et al.,
1998; Zambenedetti et al., 1998). In contrast to these studies which
examined a small number of cases and report MT-I/II is exclusively
associated with astrocytes, we demonstrate MT-I/II is also weakly
associated with pyramidal neurons in cases with high levels of local
tau pathology in a small proportion of a much larger cohort. MT-I/II is
generally considered an intracellular protein which is primarily local-
ized in the cytoplasm of astrocytes, however MT-I/II can be released
into the extracellular matrix and internalized by neurons via low den-
sity lipoprotein receptors, decreasing phosphorylation of several intra-
neuronal kinases implicated in pro-inflammatory processes and
apoptosis, and promoting neurite outgrowth and neuronal survival
(Ambjorn et al., 2008; Asmussen, Von Sperling, & Penkowa, 2009;
Chung et al., 2008; Fitzgerald et al., 2007). Furthermore, MT-I/II
expression is induced in neurons in the hippocampus of animal models
of multiple sclerosis (Grubic Kezele, Blagojevic Zagorac, Jakovac,
Domitrovic, & Radosevic-Stasic, 2017), and in adult rats following sys-
temic administration of kainic acid (Kim et al., 2003). Whether the
immunopositive neurons detected in the current study are a result of
neuronal uptake of MT-I/II or induction of MT-I/II expression is
unknown.
In the current study we demonstrate MT-I/II expression is not a
specific astrocyte response to local Alzheimer type pathology. This
finding conflicts with rodent models of AD which show prominent
upregulation of MT-I/II associated with Aβ plaques (Carrasco et al.,
2006; Hidalgo et al., 2006), but supports previous investigation of
MT-I/II in AD which also demonstrated no spatial relationship
between MT-I/II+ astrocytes and Aβ plaques or tangle pathology
(Adlard et al., 1998; Zambenedetti et al., 1998). However, in contrast
to the study by Adlard et al, which reported a significant increase in
MT-I/II expression in five MCI compared with five AD cases, we did
not identify any association between MT-I/II and Braak stage in a
large aging-representative neuropathology cohort.
Oxidative stress and metal ion dyshomeostasis are key features of
AD pathology and may contribute to the pathogenesis of disease. Zinc
plays a critical role in memory formation, regulating neuronal communi-
cation in the hippocampus (Pan et al., 2011; Wang et al., 2010), and is
highly concentrated within Aβ plaques, with depleted levels in the sur-
rounding parenchyma (Dong et al., 2003; Lovell, Robertson, Teesdale,
Campbell, & Markesbery, 1998; Sayre et al., 2000; Suh et al., 2000).
Both zinc deficiency and zinc overload elicit oxidative stress that can
lead to neuronal death (Sekler & Silverman, 2012; Wang et al., 2010).
MT play a neuroprotective role against ROS damage in AD, scavenging
hydroxyl radicals, superoxide anions, hydrogen peroxide and reactive
nitrogen radicals, and are generally considered more effective anti-
oxidants than superoxide dismutase, catalase or glutathione peroxidase
(Juarez-Rebollar, Rios, Nava-Ruiz, & Mendez-Armenta, 2017; Kumari,
Hiramatsu, & Ebadi, 1998). In the current study expression of MT-I/II
correlates with the astrocyte DDR and is induced in response to oxida-
tive stress in vitro, suggesting that astrocytes play a neuroprotective
FIGURE 3 Oxidative stress induces MT-I/II expression in human astrocytes. (a) Treatment with 50 μM H2O2 for 1 hr did not significantly alter
MT2A mRNA levels, but after 24 hr significantly upregulated MT2A expression (n = 3, p = .01). (b) Unstimulated astrocytes expressed low levels
of MT-I/II, (c) but following treatment with 50 μM H2O2 for 24 hr, increased immunostaining for MT-I/II was observed in both the cytoplasmic
and nuclear compartments. Scale bar represents 50 μm [Color figure can be viewed at wieyonlinelibrary.com]
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role in response to oxidative stress and oxidative DNA damage, and
not AD pathology, in the aging brain. In addition to their role in protect-
ing against oxidative stress, astrocytes are actively involved in the neu-
roinflammatory response in AD (Gonzalez-Reyes, Nava-Mesa, Vargas-
Sanchez, Ariza-Salamanca, & Mora-Munoz, 2017). Astrocyte expres-
sion of MT-I/II impacts the neuroimmune response in rodent models
(Manso et al., 2011; Pankhurst, Bennett, Kirkcaldie, West, & Chung,
2011), suggesting that in addition to their anti-oxidant role, MTs may
modify the microglial response in AD.
MT sequester heavy metals, regulating their availability to a range
of enzymes and transcription factors. Under normal conditions, MT-I/II
is located in the cytoplasm, however nuclear translocation of MT-I/II
has been shown to occur in response to ultra-violet damage (Hanada,
Tamai, Sawamura, Hashimoto, & Muramatsu, 1998; Jourdan et al.,
2002) and cytokine activation (Spahl, Berendji-Grun, Suschek, Kolb-
Bachofen, & Kroncke, 2003). In addition to increased expression of MT-
I/II in the cytoplasmic compartment of human astrocytes in response to
oxidative stress in vitro, we also demonstrate increased expression in
the nuclear compartment, where it likely plays a role in the requirement
of zinc for nuclear metalloenzymes and transcription factors.
While recent research has primarily focused on enhancing MT-III
as a therapeutic strategy for AD (Aikins et al., 2017; Roy et al., 2017),
the current study highlights the additional potential of targeting MT-I/
II expression. In summary we demonstrate that MT-I/II is predomi-
nantly expressed by astrocytes in the ageing brain, is associated with
the astrocyte DDR and is upregulated in response to oxidative stress
in vitro. Given the ability of MT-I/II to offer neuroprotection against
oxidative stress, modulation of MT-I/II expression is a potential target
to treat the onset and progression of cognitive impairment and
dementia.
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